EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of Refractory Macular Edema With Intraocular Triamcinolone Acetonide



Treatment of Refractory Macular Edema With Intraocular Triamcinolone Acetonide



ARVO Annual Meeting Abstract Search & Program Planner : Abstract No 507



Purpose: To evaluate the response of refractory macular edema to intravitreal injection of triamcinolone acetonide. Methods: Fifteen eyes of eleven patients with refractory macular edema (either diabetic clinically significant macular edema (CSME) or cystoid macular edema (CME), pseudophakic CME, or inflammatory CME) were identified. These patients all had little or no response to conventional treatments including focal grid laser, topical prednisolone acetate, topical ketorolac, subtenons injections of triamcinolone acetonide, oral diamox, and pars plana vitrectomy. Pre-injection Snellen visual acuity was recorded. In some cases, pre-injection fluorescein angiograms were done. Informed consent was obtained and these patients were treated with trans pars plana intravitreal injection of 0.1 cc of triamcinolone acetonide (40mg/cc). Pre and post-injection fluorescein angiograms, clinical exams, and visual acuities were compared to monitor response to therapy. Patients' subjective responses were also recorded to determine if there was any functional improvement in vision. Results: Patients' visual acuity improved an average of 1.7 Snellen lines at an average of 5 weeks after treatment. Patients that showed improvement did so by 1 month after treatment. One eye showed improvement at one month but return to baseline visual acuity by 6 weeks after injection. Two eyes which were each injected 3 times over 7 and 8 months respectively showed considerable improvement (4 and 5 lines of Snellen visual acuity respectively) for approximately 2 months after each injection, but then a gradual waning of improvement by 3 months after injection. The functional vision in 10 eyes was described by patients as slightly to somewhat better. The functional vision in 5 eyes was not noted to change at all. In all cases, on clinical exam and/or fluorescein angiography the macular edema either improved or completely resolved. No patients have yet developed cataracts, intraocular pressure spikes, vitreous hemorrhage, or retinal detachment. Conclusion: Intravitreal triamcinolone acetonide appears to be effective at reducing or eradicating refractory macular edema. However, the improvement in visual function appears less dramatic. There is suggestion that the effect is temporary, and repeat injections are likely to be necessary. Further study and monitoring of these patients will add to our knowledge of efficacy and complication rates.

(PDF emailed within 1 workday: $29.90)

Accession: 035980596

Download citation: RISBibTeXText



Related references

Efficacy and complications of intravitreal injection of triamcinolone acetonide for refractory cystoid macular edema associated with intraocular inflammation. Japanese Journal of Ophthalmology 52(5): 374-379, 2008

Delivery of intraocular triamcinolone acetonide in the treatment of macular edema. Pharmaceutics 4(1): 230-242, 2012

Intravitreal triamcinolone acetonide of triaminolone for the treatment of diabetic refractory macular edema early effect on central macular thickness and visual acuity. ARVO Annual Meeting Abstract Search & Program Planner : Abstract No 3964, 2003

Intravitreal triamcinolone acetonide for the treatment of diabetic macular edema refractory to laser photocoagulation. ARVO Annual Meeting Abstract Search & Program Planner : Abstract No 3967, 2003

Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology 116(5): 902-11; Quiz 912-3, 2009

Pars plana vitrectomy with removal of posterior hyaloid face in treatment of refractory diabetic macular edema resistant to triamcinolone acetonide. Japanese Journal of Ophthalmology 50(6): 529-531, 2006

Intravitreal triamcinolone acetonide for refractory diabetic macular edema. IOVS 42(4): S741, March 15, 2001

Intraocular triamcinolone acetonide for macular edema due to CRVO. A multifocal-ERG and OCT study. Documenta Ophthalmologica. Advances in Ophthalmology 114(1): 1-7, 2006

Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. American Journal of Ophthalmology 140(5): 958; Author Reply 958-9, 2005

Diffuse diabetic macular edema. Intraocular pressure after intravitreal triamcinolone acetonide. Der Ophthalmologe 102(2): 153-157, 2004

Intraocular pressure after intravitreal injection of triamcinolone acetonide following vitrectomy for macular edema. Journal of Glaucoma 16(2): 220-224, 2007

Triamcinolone acetonide for refractory pseudophakic cystoid macular edema after intravitreal bevacizumab. Graefe's Archive for Clinical and Experimental Ophthalmology 247(3): 427-428, 2008

Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. Journal of Cataract and Refractive Surgery 29(1): 27-33, 2003

Pilot study of intravitreal injection of triamcinolone acetonide for refractory diabetic macular edema. ARVO Annual Meeting Abstract Search & Program Planner : Abstract No 3966, 2003

Complications of intravitreal triamcinolone acetonide for macular edema and predictive factors for intraocular pressure elevation. International Journal of Ophthalmology 5(6): 719-725, 2013